Exploiting machine learning for predicting skeletal-related events in cancer patients with bone metastases
暂无分享,去创建一个
Hui Zhao | Yang Yao | Zhi-yu Wang | Xiaoting Wen | Yao-hong Lu | Yang Yao | Hui Zhao | Zhiyu Wang | Xiaoting Wen | Yaohong Lu
[1] H. Kim,et al. Prediction Model for Health-Related Quality of Life of Elderly with Chronic Diseases using Machine Learning Techniques , 2014, Healthcare informatics research.
[2] Bo-Yeong Kang,et al. Predictors of Medication Adherence in Elderly Patients with Chronic Diseases Using Support Vector Machine Models , 2013, Healthcare informatics research.
[3] Bahram Goliaei,et al. Prediction of lung tumor types based on protein attributes by machine learning algorithms , 2013, SpringerPlus.
[4] Henrik Toft Sørensen,et al. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). , 2010, The Journal of urology.
[5] Leo Breiman,et al. Statistical Modeling: The Two Cultures (with comments and a rejoinder by the author) , 2001, Statistical Science.
[6] J A Swets,et al. Measuring the accuracy of diagnostic systems. , 1988, Science.
[7] Leo Breiman,et al. Statistical Modeling: The Two Cultures (with comments and a rejoinder by the author) , 2001 .
[8] E F Cook,et al. Asymmetric stratification. An outline for an efficient method for controlling confounding in cohort studies. , 1988, American journal of epidemiology.
[9] Ivana Đurđević,et al. Classification of entrepreneurial intentions by neural networks, decision trees and support vector machines , 2010 .
[10] Zhi-yu Wang,et al. CT fluoroscopy-guided percutaneous osteoplasty for the treatment of osteolytic lung cancer bone metastases to the spine and pelvis. , 2012, Journal of vascular and interventional radiology : JVIR.
[11] M. Soloway,et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan , 1988, Cancer.
[12] Zhi-yu Wang,et al. Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis. , 2015, The oncologist.
[13] R. Coleman. Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.
[14] H. Sørensen,et al. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007) , 2011, Breast Cancer Research and Treatment.
[15] D O Hancock,et al. The value of postural reduction in the initial management of closed injuries of the spine with paraplegia and tetraplegia , 1969, Paraplegia.
[16] R. Coleman. Skeletal complications of malignancy , 1997, Cancer.
[17] R. Cook,et al. Methodology for treatment evaluation in patients with cancer metastatic to bone. , 2001, Journal of the National Cancer Institute.
[18] K. Rankin,et al. Metastatic Disease in Long Bones. A Proposed Scoring System for Diagnosing Impending Pathologic Fractures , 2014 .
[19] K. Weinfurt,et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] R. Coleman. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.
[21] G. Hortobagyi,et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases , 2000, Cancer.
[22] C. Vogel,et al. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. , 2004, The oncologist.
[23] Lucila Ohno-Machado,et al. Logistic regression and artificial neural network classification models: a methodology review , 2002, J. Biomed. Informatics.
[24] C. Langer,et al. The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer , 2008, Current opinion in oncology.
[25] J. Eastham,et al. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. , 2006, Urologic oncology.
[26] R. Coleman. Bisphosphonates: clinical experience. , 2004, The oncologist.
[27] M. Krzakowski,et al. Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors , 2004, Cancer.
[28] K. Weinfurt,et al. Health-Related Quality of Life Among Patients With Breast Cancer Receiving Zoledronic Acid or Pamidronate Disodium for Metastatic Bone Lesions , 2004, Medical care.
[29] X. Badia,et al. Impact of skeletal complications on patients’ quality of life, mobility, and functional independence , 2008, Supportive Care in Cancer.